191 related articles for article (PubMed ID: 24549574)
1. Involvement of urokinase-type plasminogen activator system in cancer: an overview.
Mekkawy AH; Pourgholami MH; Morris DL
Med Res Rev; 2014 Sep; 34(5):918-56. PubMed ID: 24549574
[TBL] [Abstract][Full Text] [Related]
2. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
3. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
4. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type plasminogen activator system and breast cancer (Review).
Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
[TBL] [Abstract][Full Text] [Related]
7. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
8. Modulators of the urokinase-type plasminogen activation system for cancer.
Hildenbrand R; Allgayer H; Marx A; Stroebel P
Expert Opin Investig Drugs; 2010 May; 19(5):641-52. PubMed ID: 20402599
[TBL] [Abstract][Full Text] [Related]
9. The urokinase plasminogen activating system in thyroid cancer: clinical implications.
Baldini E; Sorrenti S; D'Armiento E; Di Matteo FM; Catania A; Ulisse S
G Chir; 2012 Oct; 33(10):305-10. PubMed ID: 23095556
[TBL] [Abstract][Full Text] [Related]
10. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
11. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus.
Kobayashi H; Fujishiro S; Terao T
Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854
[TBL] [Abstract][Full Text] [Related]
12. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
13. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
14. Evolving role of uPA/uPAR system in human cancers.
Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
[TBL] [Abstract][Full Text] [Related]
15. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies.
Su SC; Lin CW; Yang WE; Fan WL; Yang SF
Expert Opin Ther Targets; 2016; 20(5):551-66. PubMed ID: 26667094
[TBL] [Abstract][Full Text] [Related]
16. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
17. Urokinase plasminogen activator system as a potential target for cancer therapy.
Mekkawy AH; Morris DL; Pourgholami MH
Future Oncol; 2009 Nov; 5(9):1487-99. PubMed ID: 19903074
[TBL] [Abstract][Full Text] [Related]
18. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
19. Transforming Growth Factor-Beta and Urokinase Type Plasminogen Interplay in Cancer.
Santibanez JF; Krstic J
Curr Protein Pept Sci; 2018; 19(12):1155-1163. PubMed ID: 29086689
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy.
Schmitt M; Harbeck N; Thomssen C; Wilhelm O; Magdolen V; Reuning U; Ulm K; Höfler H; Jänicke F; Graeff H
Thromb Haemost; 1997 Jul; 78(1):285-96. PubMed ID: 9198168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
